Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.

Conditions:   Pancreatic Ductal Adenocarcinoma;   Colorectal Cancer;   Gastric Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Bone Cancer;   Advanced Cancer;   Recurrent Disease;   Metastatic Tumours
Intervention:   Drug: 177Lu-3BP-227 (also called 177Lu-IPN01087)
Sponsor:   Ipsen
Not yet recruiting

https://ift.tt/2rIhAx9